Author

Dion Slaga

Institution: Genentech

Observed institution: Genentech

OpenAlex ID: A5084578065

bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies

2017 · Sanket Patke, Ji Li, et al. · mAbs · 14

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies

2010 · Veerendra Munugalavadla, Leanne Berry, et al. · Blood · 12

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity

2010 · Allen J. Ebens, Leanne Berry, et al. · Blood · 12

Abstract 1486: Pharmacodynamic response to HER2/CD3 bispecific antibody (HER2-TDB): evidence of T-cell recruitment and further rationale for combination treatment with anti-PD-L1

2016 · Ji Li, Maria Hristopoulos, et al. · Cancer Research

The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells.

2009 · Veerendra Munugalavadla, Leanne Berry, et al. · Blood

Antibody-Drug Conjugates Targeted to CD79 for the Treatment of Non-Hodgkin’s Lymphoma.

2006 · Andrew G. Polson, Shang-Fan Yu, et al. · Blood

Works count: 6

Citation count: 38

H-index: 3

I10-index: 3